Intestinal transcriptomic analysis and prediction of biomarkers associated with mucosal healing following vedolizumab treatment in ulcerative colitis using machine learning
Open Access
- 17 January 2026
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Abstract
There is an increasing need for predictors of clinical outcomes in patients with ulcerative colitis (UC). In this exploratory analysis, we aimed to analyzeKeywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 44 references indexed in Scilit:
- A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiologyNature Communications, 2023
- Emerging roles of the Hedgehog signalling pathway in inflammatory bowel diseaseCell Death Discovery, 2021
- Targeting of the Tec Kinase ITK Drives Resolution of T Cell–Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative ColitisGastroenterology, 2021
- Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment responseNature Communications, 2019
- T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammationJournal of Autoimmunity, 2019
- Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotypeClinical Immunology, 2018
- Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2018
- Distinct Chemokine Signaling Regulates Integrin Ligand Specificity to Dictate Tissue-Specific Lymphocyte HomingDevelopmental Cell, 2014
- Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune systemFEBS Letters, 2014
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005